test

Harris E Foster Jr MD

Professor of Urology; Director, Female Urology and Neuro-Urology; Residency Program Director

Biographical Info

  • Practice Locations: York Street Campus, VA Connecticut Healthcare System (West Haven, Newington), and Gaylord Hopsital
  • Residency - University of Michigan
  • Clinical Interests: Female urology, urodynamics, neurogenic bladder, male and female urinary incontinence, interstitial cystitis; voiding dysfunction; benign prostatic hyperplasia, erectile dysfunction, urologic cancers.

Dr. Harris E. Foster Jr. is board certified in urology and has specialized interests in voiding dysfunction and female urology. Particular to this area include treatment of female and male urinary incontinence, neurgogenic bladder, benign prostatic hyperplasia (PBH), interstitial cystitis, urethral diverticula and vesicovaginal fisulae. In addition, Dr. Foster treats general urological conditions such as kidney stones, erectile dysfunction, prostate cancer, superficial bladder cancer, and benign conditions involving the scrotum (hydrocele, epididymal cyst). He also performs circumcision and vasectomy in patients who desire these procedures. Dr. Foster has expertise in the evaluation of voiding dysfunction utilizing urodynamics.

Dr. Foster earned his undergraduate degree from the University of Michigan at Ann Arbor. He then graduated with honors from University of Miami School of Medicine, a member of the Alpha Omega Alpha medical honor society. Dr. Foster subsequently completed his urology residency at the University of Michigan Hospitals and joined the faculty at Yale University School of Medicine. Dr. Foster is Chief of Urology for the Veteran’s Administration Connecticut Healthcare System and is a urology consultant at the Gaylord Rehabilitation Hospital in Wallingford, Connecticut and The Hospital for Special Care in New Britain, Connecticut. He also provides urological care at the Yale University Health Services. Dr. Foster has received grants from the National Institutes of Health (NIH) to perform clinical trials investigating the pharmacologic and phytotherapeutic treatment of BPH. He was also the chairman for many years of the NIH sponsored Interstitial Cystitis Collaborative Research Network. Dr. Foster was a member of the American Board of Urology Examination Committee and has functioned as an oral board examiner for this organization. He has written numerous research publications and textbook chapters and is a reviewer for many of the major urology journals including The Journal of Urology, Urology, and Neurourology and Urodynamics. Finally, Dr. Foster has been a member of the guidelines committee for the evaluation and treatment of BPH and overactive bladder (OAB) sponsored by the American Urological Association.

Dr. Foster is dedicated to treating patients suffering from urological diseases with a particular focus on those who have voiding dysfunction. He recognizes that although most of these disorders do not affect duration of life, they can in many instances have significant if not devastating effects on quality of life. Despite being a urological surgeon, he fully understands that surgery is not frequently indicated nor is it always the best option for many patients.


International Activity

  • Update on the Evaluation and Treatment of Interstitial Cystitis
    United States(2011 - 2011)
    Presentation at the New York Medical College Department of Urology Grand Rounds Conference
  • A Mini-Symposium in Pelvic Floor Disorders: A Multidisciplinary Approach. Topic: Update on the Diagnosis and Treatment of Interstitial Cystitis.
    New Haven, United States(2008 - 2008)
    Presentation at the Yale School of Medicine at the Department of Obstetrics, Gynecology, and Reproductive Sciences
  • “The Approach to sexual dysfunction and what doctors can do about it”.
    New Haven, United States(2006 - 2006)
    Sexuality Workshop for Pre-Clinical Clerkship at the Yale School of Medicine
  • Advances in diagnosis and treatment of interstitial cystitis. Surgical management of complex urinary incontinence in females with neurologic disease. Long-term effects of medical therapy for the treatment of PBH: A clinical and basic science perspective.
    Providence, United States(2006 - 2006)
    Presentation at the Rhode Island Hospital Urology Grand Rounds
  • Recent advances in the Pharmacologic Treatment of BPH
    Canada(2006 - 2006)
    Presentation at the 2006 Annual Meeting of the Northeastern Section of the AUA
  • Moderator: Advances in interstitial cystitis
    United States(2005 - 2005)
    AUA Plenary Session 2005
  • New concepts in diagnosis and management of interstitial cystitis
    San Antonio, United States(2005 - 2005)
    Moderator at the Plenary Session at the 2005 American Urological Association Annual Meeting
  • Management of the refractory overactive bladder, Topic: Treatment of refractory overactive bladder.
    San Francisco, United States(2004 - 2004)
    Plenary Session at the 2004 American Urological Association Annual Meeting
  • Panelist: Treatment of refractory overactive bladder
    United States(2004 - 2004)
    AUA Plenary Session 2004
  • Medical management of BPH
    United States(2004 - 2004)
    Presentation at the University of Medicine and Dentistry of New Jersey Medical Grand Rounds
  • Prostate disease in the year 2004 for the primary care physician
    Pawtucket, United States(2004 - 2004)
    Presentation at the Memorial Hospital Medical Grand Rounds
  • Update on interstitial cystitis
    Hartford, United States(2003 - 2003)
    Presentation at the University of Connecticut Grand Rounds
  • Advances in the treatment of interstitial cystitis
    United States(2002 - 2002)
    Presentation at the Howard University/Washington Urological Society Grand Rounds
  • Interstitial cystitis.
    Syracuse, United States(2000 - 2000)
    Presentation at the Syracuse University Grand Rounds
  • Treatment of BPH
    Waterbury, United States(1998 - 1998)
    Presentation at St. Mary's Hospital
  • Issues in Men’s Health in Primary Care
    New Haven, United States(1998)
    Yearly lecture/class to Nurse Practitioner students at Yale School of Nursing

Education & Training

M.D.
University of Miami (1987)
Resident
University of Michigan, Ann Arbor, MI, General Surgery (1987 - 1989)
Resident
University of Michigan, Ann Arbor, MI, Urology (1989 - 1992)
Board Certification
Urology, Board Certified  (1994)

Honors & Recognition

  • Award for Urological Teaching
    Boehringer-Ingelheim Pharmaceutical Company (1999)
  • AOA (Alpha Omega Alpha) National Medical Honor Society
    (1986)
  • George Tershakovic Award (Given to 2nd year medical students with the highest National Board of Medicine score in Biochemistry)
    University of Miami School of Medicine (1985)
  • Alumni Scholarship
    University of Miami School of Medicine (1983)
  • Cardura International Competitive Award (for proposal: "The effects of chronic administration of Doxazosin on the rat prostate"
    (1998)
  • Alumni Scholarship
    University of Miami School of Medicine (1984)
  • Cardura International Competitive Award (for proposal: "The effects of chronic administration of Doxazosin on the rat prostate"
    (1999)
  • Alumni Scholarship
    University of Miami School of Medicine (1985)
  • Alumni Scholarship
    University of Miami School of Medicine (1986)
  • Alumni Scholarship
    University of Miami School of Medicine (1987)

Professional Service

  • Member, one time study section for O'Brien Urology Center submissions, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (07/01/2008 - 07/31/2008)
  • Chairman of Muscle Group, National Institutes of Health Bladder Research Progress Review Group (07/01/2001 - 07/31/2001)
  • Study Section, National Institutes of Health/National Institute of Child Health and Human Development for review of applications for RFA entitled "Epidemiologic research on female pelvic floor disorders." (04/01/2004 - 04/30/2004)
  • Peer Review Committee - SCORS, National Institutes of Health (03/01/2007 - 03/31/2007)
  • American Urological Association Overactive Bladder (OAB) Guidelines Committee (01/01/2009 - 12/31/2009)
  • Long Range Planning Committee, New England Section of American Urological Association (01/01/2008 - 12/31/2009)
  • American Urological Association Benign Prostatic Hyperplasia (BPH) Guidelines Committee (01/01/2007 - 12/31/2015)
  • American Board of Urology Oral Examination Committee (01/01/2007 - 12/31/2012)
  • Elected permanent member, Study Section, National Institutes of Health Urologic and Kidney Development and Genitourinary Diseases Study Section, Renal and Urological Studies Integrated Review Group (01/01/2006 - 12/31/2010)
  • Ad Hoc Member, Study Section, National Institutes of Health Urologic and Kidney Development and Genitourinary Diseases Study Section, Renal and Urological studies Integrated Review Group (01/01/2005 - 12/31/2006)
  • Internet Advisory Committee, American Urological Association (01/01/2005 - 12/31/2006)
  • Chairman, National Institutes of Health Interstitial Cystitis Clinical Research Network (ICCRN) (01/01/2003 - 12/31/2009)
  • Judicial and Ethics Committee, New England Section of the AUA (01/01/2003 - 12/31/2004)
  • By-Laws Committee, New England Section AUA (01/01/2001 - 12/31/2002)
  • Chairman, National Institutes of Health Interstitial Cystitis Clinical Trials Group (ICCTG) (01/01/2001 - 12/31/2003)
  • Connecticut Representative, New England Section of the AUA (01/01/1999 - 12/31/2001)
  • New England Section representative, American Urological Association Research Committee (01/01/1999 - 12/31/2001)
  • The Edwin Beer Selection Committee, The New York Academy of Medicine (01/01/1999 - 12/31/2004)
  • American Board of Urology Examination Committee (01/01/1999 - 12/31/2003)
  • Member, Societe Internationale D'Urologie (01/01/1999 - 12/31/2015)
  • Member, Doxazosin Investigators and Consultants Educational Exchange (DICE) (01/01/1998 - 12/31/2003)
  • Member, Female Urology and Neurourology (FUN) Group (01/01/1998 - 12/31/2004)
  • Study Section, National Institutes of Health/Human Genome Research Institute for review of Collaborative Recruitment Centers for African American Hereditary Prostate Cancer Study Network (01/01/1997 - 12/31/1997)
  • Editor/Associate Editor, Editorial Board, Investigative Urology Section in Journal of Urology (01/01/1997 - 12/31/2002)
  • Editorial Board, Investigative Urology section in Journal of Urology (01/01/1997 - 12/31/2002)
  • Member, Sigma Xi Scientific Research Society (01/01/1997 - 12/31/2015)
  • Member, Society of University Urologists (01/01/1997 - 12/31/2015)
  • Member, Yale Surgical Society (01/01/1997 - 12/31/2015)
  • Scientific Program Committee, New England Section of the AUA (01/01/1996 - 12/31/1996)
  • Co-chairman, Recruitment and Retention Committee for Full Scale NIH-BPH Study (01/01/1996 - 12/31/1996)
  • Member, National Association for Continence (01/01/1996 - 12/31/2015)
  • Co-chairman, Scientific Program Committee, New England Section of the AUA (01/01/1995 - 12/31/1995)
  • Member, Connecticut Chapter, Multiple Sclerosis Society Advisory Committee (01/01/1995 - 12/31/2000)
  • Scientific Program Committee, New England Section of the AUA (01/01/1994 - 12/31/1994)
  • Member, New England Section of AUA (01/01/1994 - 12/31/2015)
  • Member, Society for Female Urology and Urodynamics/Society for Urodynamics and Female Urology (SUFU) (01/01/1993 - 12/31/2015)
  • Member, American Cancer Society (Connecticut Chapter) (01/01/1992 - 12/31/2015)
  • Member, Yale Comprehensive Cancer Center (01/01/1992 - 12/31/2015)
  • Member, National Medical Association (01/01/1991 - 12/31/2015)
  • Member, American Urological Association (AUA) (01/01/1991 - 12/31/2015)
  • Member, National Medical Student Association (Vice-President University of Miami School of Medicine chapter 1986-1987) (01/01/1983 - 12/31/1987)
  • Member, Kappa Alpha Psi Fraternity (President University of Michigan chapter 1982-1983) (01/01/1980 - 12/31/2015)
  • Reviewer, Peer Review committee - SCORS, National Institutes of Health

Edit Profile